CordenPharma has appointed Michael Quirmbach as its new CEO and president, effective Aug. 1, 2019. He is going to succeed Riku Rautsola who will transition to the role of a senior advisor to the executive leadership team.

Quirmbach joined CordenPharma in October 2014 as chief business officer and has been a member of the executive leadership team. Prior to joining CordenPharma, he held several management positions at Siegfried, Dr. Reddy’s and Solvias. Quirmbach holds a degree in chemistry and a PhD from the Max Planck Research Group at the Institute for Organic Catalysis Research in Rostock, Germany, as well as an MBA from La Salle University in Philadelphia, USA.